What's better than momentum? Mo' momentum.
Let's take a closer look at five of this past week's biggest scorchers.
|
Company |
April 20 | Weekly Gain | My Watchlist |
|---|---|---|---|
|
Human Genome Sciences |
$14.36 | 100% | Add |
|
Endocyte |
$7.41 | 95% | Add |
|
Stratasys |
$47.85 | 33% | Add |
|
Vringo |
$3.95 | 30% | Add |
|
Sequenom |
$5.01 | 26% | Add |
Source: Barron's.
Human Genome Sciences doubled after rebuffing an unsolicited buyout offer. Even though it was a longtime partner of the company with the surprise bid, Human Genome Sciences wants to see if anyone else is willing to raise the offer of $13 a share that it turned down.
Endocyte nearly doubled after striking a licensing deal with Merck for its lead cancer-tackling product, vintafolide.
Stratasys climbed after the maker of 3-D printers moved to acquire privately held Israeli peer Objet. The combination will make Statasys a bigger player in the expensive but promising realm of 3-D printing.
Vringo soared 30% after a filing revealed that Mark Cuban acquired a 7.4% stake in the company. Vringo is a small app maker that generated just $714,000 in revenue last year. However, last month it struck a deal to merge with a company that holds a few patents from former dot-com darling Lycos.
Sequenom moved higher after announcing an agreement with health care cost-management provider MultiPlan to offer its genetic analysis test for pregnant women at increased risk for fetal aneuploidy.
More winners for you
It was a great week for these five stocks. If you want to get an early read on some of tomorrow's major gainers, here's a special report on three hidden winners in a booming industry. The report is free -- like this article -- but it won't be around forever, so check it out now.
